Home > BRISA > Search result
COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.


Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 4

Perspectivas de tratamiento para COVID-19 (en progreso)

Centro Nacional de Excelencia Tecnológica en Salud.
CONTEXTO: Debido a la contingencia por COVID-19 provocada por el nuevo coronavirus, SARS-CoV-2, en la actualidad hay una intensa investigación de alternativas terapéuticas que sean seguras y eficaces. (Hay registrados 2208 protocolos de estudios en ClinicalTrials.gov1). Con el propósito de conocer el ...
Coronavirus Infections/drug therapy, Pneumonia, Viral/drug therapy, Immunoglobulins, Intravenous/therapeutic use, Dexamethasone/therapeutic use, Ivermectin/therapeutic use, Chloroquine/therapeutic use, Hydroxychloroquine/therapeutic use, Lopinavir/therapeutic use, Ritonavir/therapeutic use, Sofosbuvir/therapeutic use, Ribavirin/therapeutic use, Thymosin/therapeutic use, Darunavir/therapeutic use, Cobicistat/therapeutic use, Technology Assessment, Biomedical, Health Evaluation
Fulltext

Intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019 (COVID-19)

Perú. Ministerio de Salud. Instituto Nacional de Salud.
INTRODUCCIÓN: En diciembre del 2019 se identificó en Wuhan (China) una serie de pacientes con infecciones respiratorias que en algunos casos evolucionaban en una neumonía viral grave, entre el 1 al 5% de los casos requerían de cuidados intensivos. El 7 de enero del 2020, las autoridades chinas anunci...
Coronavirus Infections/drug therapy, Pneumonia, Viral/drug therapy, Hydroxychloroquine/therapeutic use, Lopinavir/therapeutic use, Ritonavir/therapeutic use, Interferons/therapeutic use, Interferon-alpha/therapeutic use, Technology Assessment, Biomedical, Health Evaluation
Fulltext

Lopinavir/ritonavir para COVID-19

Instituto de Efectividad Clínica y Sanitaria.
CONTEXTO CLÍNICO: La Enfermedad por el Coronavirus 2019 (COVID–19, por su sigla en inglés Coronavirus Disease 2019) es una enfermedad respiratoria de humanos producida por un nuevo coronavirus identificado con la sigla 2019–nCoV. El 11 de marzo de 2020 la Organización Mundial de la Salud (OMS) dec...
Lopinavir/therapeutic use, Ritonavir/therapeutic use, Coronavirus Infections/drug therapy, Pneumonia, Viral/drug therapy, Technology Assessment, Biomedical, Cost-Benefit Analysis
Fulltext

Informe diário de evidências: COVID-19 busca realizada em 22 de abril de 2020

Brasil. Ministério da Saúde. Secretaria de Ciência,Tecnologia e Insumos Estratégicos em Saúde.
O objetivo da revisão sistemática foi investigar a eficácia e a segurança de tratamentos com antivirais para COVID-19, SARS e MERS. Ao todo, 22 estudos foram incluídos: 1 ensaio clínico, 16 séries de casos e 5 relatos de caso. Os antivirais mais utilizados foram lopinavir / ritonavir, oseltamivir,...
Betacoronavirus/drug effects, Pneumonia, Viral/drug therapy, Coronavirus Infections/drug therapy, Anti-Retroviral Agents/administration & dosage, Oseltamivir/therapeutic use, Lopinavir/therapeutic use, Ritonavir/therapeutic use, Ribavirin/therapeutic use, Antiparasitic Agents/administration & dosage, Antifungal Agents/administration & dosage, Therapies, Investigational/instrumentation, Disease Progression, Technology Assessment, Biomedical
Fulltext